The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA.
PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
More News: Abatacept | Actemra | Arthritis | Cardiology | Cardiovascular | Heart | Heart Attack | Heart Failure | Methotrexate | Orencia | Prednisolone | Rheumatoid Arthritis | Rheumatology | Rituxan | Stroke